68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

Not Recruiting

Trial ID: NCT02488070

Age - 18 Years-N/A Condition - Prostate Cancer, Prostate - Localized Gender - Male Accepting Healthy Volunteers - No

Purpose

This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.

Official Title

68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study

Stanford Investigator(s)

Steven Hancock, MD
Steven Hancock, MD

Professor of Radiation Oncology (Radiation Therapy), Emeritus

Geoffrey Sonn
Geoffrey Sonn

Associate Professor of Urology and, by courtesy, of Radiology (Body MRI)

Andreas Loening
Andreas Loening

Assistant Professor of Radiology (Body MRI)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

Eligibility


Inclusion Criteria:

   - Provides written informed consent

   - Known diagnosis of prostate cancer

   - Patient has suspected recurrence based on biochemical data (prostate specific antigen
   [PSA] > 2 ng/mL)

   - Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

   - Unable to provide informed consent

   - Inability to lie still for the entire imaging time

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the Investigator, may significantly interfere
   with study compliance

View More
View Less

Intervention(s):

drug: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)

procedure: Computed Tomography

procedure: Magnetic Resonance Imaging

procedure: Positron Emission Tomography

procedure: Positron Emission Tomography

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
ccto-office@stanford.edu
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine